2017年第一版：王俊興、王英偉、石崇良、李宜恭、林宏榮、侯文萱、徐圭璋、翁文能、張坤來、梁蕙雯、陳可欣、陳厚全、陳景寧、黃奕修、廖熏香、蔡景耀、譚家偉(依姓名筆劃排序) 　游育苓、吳碧娟、張靜怡 2019年第二版：李宜恭、侯文萱、紀景琪、翁逸豪、陳可欣、陳祖裕、黃奕修、廖熏香、劉人瑋、劉建良、蔡景耀、鄭浩民(依姓名筆劃排序) 　陳嘉珮、吳碧娟、蔡庚君

一、界定範圍：
依國民健康署統計台灣糖尿病患者每10人約有一位，年齡層越大，發生率越高。失明是糖尿病患者主要擔心之併發症之ㄧ。黃班部水腫病變是糖尿病病人常見視力喪失的原因之ㄧ。目前三種治療方式，包括抗新生血管藥物眼球內注射、類固醇類藥物眼球內注射、雷射選擇，三種治療在療程、返診頻率、治療效果、副作用、與負擔費用之差異，此外，眼球內注射之健保給付在審核通過後，有其給付上限，造成民眾(病人)對於治療選擇之不確定性高。
二、實證資料
依實證之臨床問題(patient and/or problem、intervention、comparison of intervention、clinical outcome，PICO)分類
(1) 適用對象/狀況（P）：糖尿病人出現視力模糊，且診斷具有黃斑部水腫病變者。
(2) 決策選項（I、C）：眼球內注射：抗新生血管藥物、類固醇類
；雷射。
(3) 結果，如病人偏好、風險、好處等（O）：改善視力或減緩惡化。
三、利益衝突聲明、製作日期、資金來源
本決策輔助工具為財團法人醫院評鑑暨醫療品質策進會承接衛生福利部「105年度醫病共享決策推廣計畫」項下開發，並於「107年度醫病共享決策推廣計畫」項下更新，資金來源為前述兩項計畫之計畫經費編列，最終更新日期為108年12月05日。
四、更新策略
本決策輔助工具於106年開發，維持每2年檢視最新實證並評估更新，並已於108年完成更新。

1. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol. 103 (1985) 1796-1806.
2. Ciulla TA, Amador AG, Zinman B, Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies, Diabetes Care. 26 (2003) 2653-2664.
3. Elman MJ, Ayala A, Bressler NM, et al, Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results, Ophthalmology. 122 (2015) 375-381.
4. Schmidt-Erfurth U, Lang GE, Holz FG, et al, Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study, Ophthalmology. 121 (2014) 1045-1053.
5. Wells JA, Glassman AR, Ayala AR, et al, Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial, Ophthalmology. 123 (2016) 1351-1359.
6. Boyer DS, Yoon YH, Belfort R, Jr., et al, Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema, Ophthalmology. 121 (2014) 1904-1914.
7. Luttrull JK, Dorin G, Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review, Curr Diabetes Rev. 8 (2012) 274-284.
8. Malcles A, Dot C, Voirin N, et al, SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension, Retina. 37 (2017) 1352-1359.
9. Brown DM, Schmidt-Erfurth U, Do DV, et al, Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies, Ophthalmology. 122 (2015) 2044-2052.
10. Avery RL, Gordon GM, Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis, JAMA Ophthalmol. 134 (2016) 21-29.
11. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis, Cochrane Database Syst Rev. 10 (2018) CD007419.
12. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes, Cochrane Database Syst Rev. 1 (2008) CD005656.